Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Abe of JPA Proposes Exempting Ordinary Pharmacies from Medical Fee Cut Rule: Chuikyo
June 12, 2015
- Shiozaki’s Pitch on 80% Generic Target by FY2020 Fails to Resonate
June 11, 2015
- NHI Price Revision in FY2017 and Annual NHI Price Revision Should Be Discussed Separately: Shirakawa
June 11, 2015
- Chuikyo Begins Discussions on FY2016 NHI Pricing Reform; Drug Pricing Organization to Present Views at Next Meeting
June 11, 2015
- PAFSC Second Committee to Discuss Olanexidine, Zosyn on June 17
June 10, 2015
- LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
- Kaketsuken Suspends Shipments of 12 Products Due to Modifications of Approved Manufacturing Procedures
June 9, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 25 - June 7
June 8, 2015
- MHLW’s Jo Urges Generic Makers to Formulate Careful Investment Plans
June 8, 2015
- Govt Working Group Suspicious about Supply Limitation Hindering Generic Goal
June 8, 2015
- PAFSC 1st Committee Backs Approval of Lilly’s GLP-1 Receptor Agonist Dulaglutide
June 8, 2015
- 8 Members of PAFSC’s Pharmaceutical Affairs Council to Be Ousted for Violating COI Rules
June 8, 2015
- Roughly 60 Products Submitted as Candidates for Review under Sakigake Designation System
June 8, 2015
- LDP Study Group Agrees on Good Balance between Generic Promotion, Innovation
June 5, 2015
- Prime Minister Abe Asks Health Minister to Formulate New Measures against Cancer by Year-End
June 4, 2015
- MHLW to Launch Switch OTC Panel as Early as Summer
June 3, 2015
- MHLW Calls for Revision of Package Insert for Xalkori
June 3, 2015
- MHLW Stands by “80% in FY2020” as New Generic Use Target, Says It’s “Barely Reachable”
June 2, 2015
- MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
- JPMA Says Generic Target Has Huge Impact on Innovation, Balanced Approach Needed
June 1, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…